MitraClip, Abbott Park, Ill.-based Abbott’s minimally invasive transcatheter mitral valve repair (TMVR) system, was chosen from a field of 17 other nominees, according to a news release. MitraClip is delivered to the heart through a vein in the leg and clips portions of the leaflets or flaps of the mitral valve together to reduce the backflow of blood.
Last month, Abbott’s fourth-generation MitraClip won CE Mark approval as a non-surgical option for treating mitral regurgitation (MR) or a leaky heart valve. The device already has approval in the U.S., having won an FDA nod in July 2019. The MitraClip system secured its first FDA approval in 2013 and, in January of this year, the FDA approved a clinical trial to study the effectiveness of MitraClip in people eligible for open-heart surgery.
The victory is Abbott’s second in as many years in the category, having received the award for its FreeStyle Libre 14-day system for continuous glucose monitoring in 2019.
“MitraClip is a first-of-its-kind, life-saving device that has transformed the lives of more than 100,000 people living with leaky mitral valves, many of whom were not treatable with open-heart mitral valve surgery – leaving them with few to no options,” SVP of Abbott’s structural heart business Michael Dale said in the release. “We are honored by this prestigious recognition by the Galien Foundation – a testament to our relentless pursuit to develop innovative treatment options for people living with structural heart conditions that allow them to live better, healthier lives.”
Abbott also noted that the Prix Galien award follows numerous recognitions in recent times, with its BinaxNow rapid COVID-19 test being recognized as a top innovation by the Chicago Innovation Awards and its Amplatzer Piccolo occluder winning an Edison award for human-centered design in prenatal and infant care, among other notable awards and recognitions.